CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01872910
NCT01872910Phase 2Completed

Evaluation of the Acute Analgesic Efficacy of a Single Dose of LY3023703 in Patients With Postsurgical Dental Pain: A Parallel, Double-Blind, Randomized, Placebo and Positive Control Study

Eli Lilly and Company·interventional·Posted Jun 7, 2013·Updated Sep 23, 2019

In Brief

A Phase 2 clinical trial evaluating Placebo, LY3023703, and 1 other intervention for Acute Pain. Completed, enrolled 124 participants across 1 site.

Detailed Summary

The main purpose of this study is to test if a single dose of LY3023703 relieves pain after wisdom teeth removal. The study will last about one week for each participant, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 7, 2013
Enrollment StartJun 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.1 years ago

Interventions

Placebodrug

Administered orally

LY3023703drug

Administered orally

Celecoxibdrug

Administered orally